ACA
SRPT icon

Apis Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Apis Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,500
Closed -$1.29M – 34
2019
Q2 		$1.29M Sell
8,500
-1,500
-15% -$182K 1.93% 15
2019
Q1 		$1.19M Sell
10,000
-2,000
-17% -$257K 1.44% 20
2018
Q4 		$1.31M Buy
+12,000
New +$1.5M 1.76% 14

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Apis Capital Advisors's SRPT Position: Q3 2019 in Review

Apis Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 8,500 shares — an estimated $1.29M sold.

Apis Capital Advisors first reported a position in SRPT in Q4 2018 and held it in 3 quarters. The position peaked at $1.31M in Q4 2018. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Apis Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Apis Capital Advisors sold 8,500 Sarepta Therapeutics shares in Q3 2019, an estimated $1.29M.
  • Apis Capital Advisors first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 3 quarters.
  • Apis Capital Advisors's Sarepta Therapeutics position peaked at $1.31M in Q4 2018.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Apis Capital Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.